Bicycle Therapeutics plc announced the presentation of data on zelenectide pevedotin's anti-tumor activity at the upcoming 2024 San Antonio Breast Cancer Symposium, including impactful findings in triple-negative breast cancer patients.
Company Information
Company
Bicycle Therapeutics
About
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bicycle Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
